MNKD Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$7.97median target· current $4.07 (+95.8%)8 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 119.05
EPS (TTM)$-0.15-34.9% YoY
Profit margin-11.1%HEALTHCARE
Market cap$1.33BSmall cap
Valuation
- Forward P/E
- 119.05
- PEG ratio
- 4.39
- P/B
- 187.85
- P/S (TTM)
- 3.37
- EV/EBITDA
- 76.29
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -0.8%
- Revenue growth YoY
- 42.9%
- Dividend yield
- —
- Beta
- 1.10
Last earnings
Aug 5, 2026 · Estimate $-0.02 · Reported $-0.06
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About MannKind Corp
Company profileMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 CASPER STREET, DANBURY, CT
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$1.33B
Shares outstanding$321.5M
52W high$6.51
52W low$2.23
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent